微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 81.33% | 3.76% | 0.81% | 19/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 80.67% | 3.21% | 0.65% | 19/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 80.16% | 5.33% | 2.33% | 17/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 78.33% | 1.24% | -0.07% | 22/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 78.38% | 1.03% | 0.28% | 21/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 78.16% | 2.37% | 2.71% | 22/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 76.1% | 0.18% | -1.64% | 24/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 77.37% | -1.74% | -0.27% | 28/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 77.58% | -3.18% | 1.6% | 28/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 76.36% | -4.35% | 0.51% | 28/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 75.97% | -5.28% | -3.52% | 28/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 78.74% | 0.84% | -1.73% | 22/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 80.13% | 2.16% | 0.37% | 20/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 79.83% | 3.46% | -0.47% | 25/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 80.21% | 4.22% | 2.71% | 21/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 78.09% | 6.77% | -0.44% | 30/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 78.43% | 8.67% | 1.65% | 23/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 77.16% | 10.28% | 0.26% | 25/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 76.96% | 12.83% | 5.23% | 21/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 73.13% | -0.17% | 1.33% | 33/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 72.17% | -1.72% | 3.16% | 29/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 69.96% | -3.33% | 2.58% | 33/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 68.21% | -7.74% | -6.9% | 30/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.26% | 1.3% | -0.24% | 30/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 73.44% | 2.98% | 1.47% | 21/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 72.38% | 4.25% | -2.1% | 25/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 73.93% | 8.6% | 2.23% | 18/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 72.32% | -2.15% | 1.41% | 30/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 71.31% | -4.99% | 2.71% | 19/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.43% | -8.2% | 1.99% | 21/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 68.08% | -13.18% | -7.89% | 25/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 73.91% | -1.72% | -1.53% | 22/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 75.05% | 0.19% | -0.77% | 14/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 75.63% | 3.32% | -3.54% | 9/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 78.41% | 2% | 4.27% | 8/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 75.2% | 6.82% | 0.38% | 15/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 74.91% | -3.23% | 2.33% | 9/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 73.2% | 2% | 3.99% | 10/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |